Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd (LFWD) delivers cutting-edge medical devices that redefine physical rehabilitation, from clinical exoskeletons to anti-gravity systems. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in mobility technology and market strategy.
Access all official Lifeward press releases and financial announcements in one centralized location. Track developments across key areas including product launches, regulatory milestones, and strategic partnerships in the United States, Israel, and Germany.
Explore updates on proprietary innovations like the AlterG systems with DAP technology and the ReStore Exo-Suit. Stay informed about operational efficiencies, R&D breakthroughs, and compliance achievements that underscore Lifeward’s leadership in rehabilitation solutions.
Bookmark this page for streamlined access to verified information directly impacting LFWD’s position in the global medical device sector. Regular updates ensure you never miss critical developments shaping the future of physical recovery technologies.
Lifeward, formerly known as ReWalk Robotics (NASDAQ: LFWD), will be presenting at the Sidoti Small Cap Conference on June 12-13, 2024. CEO Larry Jasinski and CFO Mike Lawless will lead the presentation and conduct one-on-one meetings with investors. The presentation will start at 9:15 AM EDT on June 12 and will be accessible live. Lifeward will also host virtual one-on-one sessions with investors during the conference. Registration for the presentation and individual meetings is free and open to all interested investors through the Sidoti website.
Lifeward (NASDAQ: LFWD) reported a Q1 2024 revenue increase of 340% year-over-year to $5.3 million, driven by a new Medicare payment for ReWalk Personal Exoskeletons, resulting in 14 approved claims. However, the gross margin declined from 46.4% to 26.4%, mainly due to low sales volume of AlterG products. Operating expenses rose to $7.9 million, leading to an operating loss of $6.5 million and a net loss of $6.3 million, or $0.73 per share. Liquidity stood at $20.7 million in cash with no debt. The company anticipates 2024 revenue between $28 to $32 million, expecting better performance in Q2 due to enhanced Medicare reimbursements and a more effective sales team.
Lifeward, a global market leader in rehabilitation solutions, will report its first quarter 2024 financial results on May 15, 2024. The company aims to revolutionize rehabilitation, recovery, and life's pursuits for those with physical limitations or disabilities. The earnings call will be hosted by CEO Larry Jasinski and CFO Michael Lawless.
FAQ
What is the current stock price of Lifeward (LFWD)?
What is the market cap of Lifeward (LFWD)?
